NASDAQ: SEEL - Seelos Therapeutics, Inc.

Altı ay boyunca karlılık: -69.53%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Seelos Therapeutics, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders.

daha fazla ayrıntı
The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 1999-04-19
ISIN US81577F1093
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://seelostherapeutics.com
Цена ао 0.39
Günlük fiyat değişimi: 0% (0.39)
Haftalık fiyat değişimi: 0% (0.39)
Aylık fiyat değişimi: 0% (0.39)
3 ayda fiyat değişimi: 0% (0.39)
Altı ayda fiyat değişimi: -69.53% (1.28)
Yıllık fiyat değişimi: -15.6% (0.4621)
3 yılda fiyat değişimi: -53.37% (0.8363)
5 yılda fiyat değişimi: -19.59% (0.485)
Yılbaşından bu yana fiyat değişimi: 0% (0.39)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 3.47 5
P/BV -0.2281 0
P/E 0 0
EV/EBITDA -0.4668 0
Toplam: 4.25

Yeterlik

İsim Anlam Seviye
ROA, % -699.19 0
ROE, % 113.05 10
Toplam: 3.33

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.3518 10
Toplam: 9

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -61.77 0
karlılık Ebitda, % 38.03 5
karlılık EPS, % 118.38 10
Toplam: 3.8
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Sabby Management, LLC 393091 0.24
Gendell, Jeffrey L. 224818 0.14
Vanguard Group Inc 172423 0.11
Wealth Effects LLC 120174 0.07
Blackrock Inc. 56466 0.03
Modera Wealth Management, LLC 40792 0.03
Geode Capital Management, LLC 40390 0.03
Mirae Asset Global Investments Co., Ltd. 29992 0.02
Woodline Partners LP 24152 0.01
Osaic Holdings Inc 21464 0.01



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Anthony Marciano Chief Communications Officer N/A
Gopal Krishna Ph.D. Head of Manufacturing & Technical Operations N/A
Tim Whitaker M.D. Chief Medical Officer N/A
Ms. Karen Fusaro Senior VP & Head of Clinical Operations N/A

Adres: United States, New York. NY, 300 Park Avenue - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://seelostherapeutics.com